GPS Wealth Strategies Group LLC Sells 1,686 Shares of Edwards Lifesciences Corporation $EW

GPS Wealth Strategies Group LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 17.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,812 shares of the medical research company’s stock after selling 1,686 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Edwards Lifesciences were worth $611,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $27,000. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $28,000. Costello Asset Management INC bought a new stake in Edwards Lifesciences in the 1st quarter valued at $29,000. Finally, NewSquare Capital LLC boosted its holdings in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 1.5%

Shares of Edwards Lifesciences stock opened at $82.86 on Thursday. The stock has a market capitalization of $48.65 billion, a P/E ratio of 11.92, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $77.72 and a 200 day simple moving average of $77.18. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $87.09.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter last year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on EW. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Finally, Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.